Baclofen and potential therapeutic use: Studies of neuronal survival

Alessandro Dario, Rossana Pisani, Simone Sangiorgi, Andrea Soragna, Marcella Reguzzoni, Marina Protasoni, Federico Pessina, Riccardo Fesce, Antonio Peres, Giustino Tomei

Research output: Contribution to journalArticle

Abstract

Up to now, baclofen (a GABAB receptor agonist) has been used for the treatment of severe spasticity unresponsive to oral antispasmodics. Although in humans it is usually administered at 2 mg/ml, the dosage to be used in the treatment of other diseases is unknown. For this reason, it is important to determine the safe maximum dosage and toxicity at the clinically used concentration. Primary cortical neurons represent a useful model to test the safety of baclofen. We performed a colorimetric assay (MTT test) as well as electron microscopy investigations, to determine neuronal survival after the treatment with baclofen at a concentration of 2 and 4 mg/ml. Our results demonstrated that, in our experimental model, neither concentration affected neuronal survival. Considering the above results, we can conclude that at the used concentrations, this drug is safe and its clinical use should be encouraged.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalEuropean Journal of Pharmacology
Volume550
Issue number1-3
DOIs
Publication statusPublished - Nov 21 2006

Keywords

  • Baclofen
  • Colorimetric assay
  • Neuronal survival
  • Primary cortical neurons
  • Spasticity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Fingerprint Dive into the research topics of 'Baclofen and potential therapeutic use: Studies of neuronal survival'. Together they form a unique fingerprint.

  • Cite this

    Dario, A., Pisani, R., Sangiorgi, S., Soragna, A., Reguzzoni, M., Protasoni, M., Pessina, F., Fesce, R., Peres, A., & Tomei, G. (2006). Baclofen and potential therapeutic use: Studies of neuronal survival. European Journal of Pharmacology, 550(1-3), 33-38. https://doi.org/10.1016/j.ejphar.2006.08.068